NCT03964506View on ClinicalTrials.gov

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2027

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic LeukemiaAtypical Chronic Myeloid LeukemiaChronic Monocytic LeukemiaMyelofibrosisMyelodysplastic/Myeloproliferative Neoplasm
Interventions
DRUG

Hyperbaric oxygen

Reduced intensity conditioning Fludarabine and Melphalan with Hyperbaric Oxygen and Allogeneic Hematopoietic Stem Cell Transplant

Trial Locations (1)

14642

RECRUITING

Wilmot Cancer Institute, University of Rochester, Rochester

All Listed Sponsors
lead

Omar Aljitawi

OTHER